.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Covington
US Army
Express Scripts
Farmers Insurance
McKesson
Mallinckrodt
Merck
Cipla
McKinsey

Generated: July 26, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021862

« Back to Dashboard
NDA 021862 describes NEVANAC, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the NEVANAC profile page.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.

Summary for NDA: 021862

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Ophthalmic Agents

Pharmacology for NDA: 021862

Suppliers and Packaging for NDA: 021862

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEVANAC
nepafenac
SUSPENSION/DROPS;OPHTHALMIC 021862 NDA Alcon Laboratories, Inc. 0065-0002 0065-0002-01 1.5 mL in 1 BOTTLE, PLASTIC (0065-0002-01)
NEVANAC
nepafenac
SUSPENSION/DROPS;OPHTHALMIC 021862 NDA Alcon Laboratories, Inc. 0065-0002 0065-0002-03 3 mL in 1 BOTTLE, PLASTIC (0065-0002-03)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION/DROPS;OPHTHALMICStrength0.1%
Approval Date:Aug 19, 2005TE:RLD:Yes
Patent:► SubscribePatent Expiration:Dec 2, 2025Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Dec 2, 2025Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Jan 31, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING OCULAR INFLAMMATION

Expired Orange Book Patents for NDA: 021862

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
NEVANAC
nepafenac
SUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Baxter
Medtronic
Johnson and Johnson
Moodys
Healthtrust
US Army
Cerilliant
Argus Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot